KRW 15130.0
(-2.64%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 252.14 Billion KRW | 33.87% |
2022 | 188.35 Billion KRW | 27.33% |
2021 | 147.92 Billion KRW | 121.25% |
2020 | 66.86 Billion KRW | 7.34% |
2019 | 62.28 Billion KRW | 21.45% |
2018 | 51.28 Billion KRW | 170.37% |
2017 | 18.96 Billion KRW | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 227.1 Billion KRW | -0.42% |
2024 Q1 | 228.05 Billion KRW | -9.56% |
2023 Q1 | 188.46 Billion KRW | 0.06% |
2023 FY | 252.14 Billion KRW | 33.87% |
2023 Q4 | 252.14 Billion KRW | 12.3% |
2023 Q3 | 224.52 Billion KRW | 18.72% |
2023 Q2 | 189.13 Billion KRW | 0.36% |
2022 Q4 | 188.35 Billion KRW | -8.19% |
2022 Q3 | 205.15 Billion KRW | 4.25% |
2022 Q2 | 196.79 Billion KRW | 34.06% |
2022 Q1 | 146.8 Billion KRW | -0.76% |
2022 FY | 188.35 Billion KRW | 27.33% |
2021 Q2 | 68.21 Billion KRW | 3.4% |
2021 Q4 | 147.92 Billion KRW | -0.77% |
2021 FY | 147.92 Billion KRW | 121.25% |
2021 Q1 | 65.97 Billion KRW | -1.33% |
2021 Q3 | 149.07 Billion KRW | 118.55% |
2020 Q1 | 63.59 Billion KRW | 2.1% |
2020 FY | 66.86 Billion KRW | 7.34% |
2020 Q3 | 67.45 Billion KRW | 1.79% |
2020 Q4 | 66.86 Billion KRW | -0.88% |
2020 Q2 | 66.27 Billion KRW | 4.21% |
2019 Q4 | 62.28 Billion KRW | 0.0% |
2019 FY | 62.28 Billion KRW | 21.45% |
2019 Q3 | - KRW | 0.0% |
2019 Q1 | - KRW | 0.0% |
2018 Q1 | - KRW | 0.0% |
2018 FY | 51.28 Billion KRW | 170.37% |
2017 FY | 18.96 Billion KRW | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
HLB Co., Ltd. | 751.72 Billion KRW | 66.457% |
iNtRON Biotechnology, Inc. | 98.61 Billion KRW | -155.689% |
BINEX Co., Ltd. | 257.01 Billion KRW | 1.893% |
Bioneer Corporation | 315.48 Billion KRW | 20.077% |
Anterogen.Co.,Ltd. | 149.43 Billion KRW | -68.737% |
MEDIPOST Co., Ltd. | 449.39 Billion KRW | 43.892% |
CrystalGenomics, Inc. | 243.11 Billion USD | -3.715% |
Helixmith Co., Ltd | 227.27 Billion KRW | -10.941% |
Chabiotech Co.,Ltd. | 1725.57 Billion KRW | 85.388% |
Medy-Tox Inc. | 611.62 Billion KRW | 58.774% |
Peptron, Inc. | 52.49 Billion KRW | -380.317% |
Amicogen, Inc. | 467.09 Billion KRW | 46.018% |
Genexine, Inc. | 376.58 Billion KRW | 33.044% |
HLB Therapeutics Co.,Ltd. | 200.79 Billion KRW | -25.574% |
LegoChem Biosciences, Inc. | 189.5 Billion KRW | -33.058% |
ALTEOGEN Inc. | 256.09 Billion KRW | 1.544% |
PharmaResearch Co., Ltd. | 535.28 Billion KRW | 52.894% |
SillaJen, Inc. | 76.71 Billion KRW | -228.681% |
OliX Pharmaceuticals,Inc | 102.82 Billion KRW | -145.219% |
Genomictree Inc. | 132.84 Billion KRW | -89.807% |
MedPacto, Inc. | 80.47 Billion KRW | -213.326% |
D&D Pharmatech | 79.2 Billion KRW | -218.353% |
EASY BIO,Inc. | 172.04 Billion KRW | -46.562% |
GI Innovation, Inc. | 81.34 Billion KRW | -209.991% |